Quantcast
Last updated on April 18, 2014 at 12:39 EDT

Latest Rosuvastatin Stories

2011-03-16 00:00:30

New Partnership Kicks Off During National Nutrition Month, Bringing Simple, Low-Cholesterol Recipes Directly to Your Kitchen Wilmington, DE (PRWEB) March 15, 2011 AstraZeneca (NYSE:AZN) today announced the launch of a partnership with Food Universityâ“ž¢ "” a culinary education and entertainment platform "” to educate people about the importance of maintaining a healthy diet as one way to help manage cholesterol. In support of its...

2011-03-14 08:00:00

WILMINGTON, Del., March 14, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the launch of a partnership with Food University(TM) -- a culinary education and entertainment platform -- to educate people about the importance of maintaining a healthy diet as one way to help manage cholesterol. In support of its cholesterol-lowering medication CRESTOR® (rosuvastatin calcium), the AstraZeneca partnership with Food University aims to empower people to take control...

2011-01-27 04:07:00

NEW YORK, Jan. 27, 2011 /PRNewswire/ -- Get content from AstraZeneca at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=0be570e4-bf68-4c0b-9777-4d22d679e195# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for the full year was unchanged at constant exchange rates (CER) at $33,269 million. Strong revenue growth in markets outside the US (up 7% at CER) broadly offset the loss of more than $1.6 billion of revenue in the US from generic competition...

6388b3719f3ae20b74c8355ad2f4eaff1
2011-01-19 10:35:00

Healthy people may derive no benefit from taking cholesterol-lowering statins, according to a review of previous studies. The report, published in The Cochrane Library concluded that statins reduced death rates in high-risk patients but said there was no evidence to justify their use in people at low risk of developing heart disease. The National Institute for Health and Clinical Excellence recommends statins for people who have a 20 percent or greater chance of developing cardiovascular...

2010-12-22 16:00:00

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD(TM) (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011. A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food...

2010-12-22 16:00:00

ABBOTT PARK, Ill., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD(TM) (rosuvastatin / fenofibric acid delayed release) Capsules. The companies reached this decision after careful consideration of the Complete Response Letter received from the U.S. Food and Drug Administration, the resulting regulatory delay and the commercial attractiveness of the product in...

2010-12-06 07:00:00

HAIKOU CITY, China, Dec. 6, 2010 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced the completion of clinical trials of the cholesterol-lowering drug, rosuvastatin (generic version of Crestor), which the Company intends to commercialize in the large and expanding Chinese healthcare market. Rosuvastatin helps reduce low-density lipoprotein...

2010-11-29 11:00:00

Patent filing is based on synergistic findings suggesting enhanced plaque management with RVX-208 in combination with statins TSX Exchange Symbol: RVX CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial. A new patent application has been filed for novel dosing...

2010-11-18 09:00:00

BURLINGTON, Mass., Nov. 18, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in the treatment of dyslipidemia, surveyed cardiologists and primary care physicians (PCPs) now perceive AstraZeneca's Crestor's ability to reduce mortality comparable to Pfizer's Lipitor. This finding has changed from Decision Resources' 2009 analysis in which surveyed cardiologists viewed Lipitor as significantly...

2010-11-17 17:37:47

Widely prescribed for their cholesterol-lowering properties, recent clinical research indicates that statins can produce a second, significant health benefit: lowering the risk of severe bacterial infections such as pneumonia and sepsis. A new explanation for these findings has been discovered by researchers at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy & Pharmaceutical Sciences, who describe for the first time how statins activate the...